Pacira Biosciences (NASDAQ:PCRX) had its price objective raised by Northland Securities from $50.00 to $54.00 in a note issued to investors on Tuesday, The Fly reports. The brokerage presently has a “market perform” rating on the stock. Northland Securities’ target price would suggest a potential upside of 22.48% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on the stock. ValuEngine upgraded shares of Pacira Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Guggenheim assumed coverage on shares of Pacira Biosciences in a research report on Tuesday, May 26th. They set a “neutral” rating for the company. Stifel Nicolaus dropped their target price on shares of Pacira Biosciences from $49.00 to $48.00 and set a “hold” rating for the company in a research report on Thursday, May 7th. BidaskClub cut shares of Pacira Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, May 29th. Finally, TheStreet upgraded shares of Pacira Biosciences from a “d+” rating to a “c-” rating in a research report on Monday, May 11th. Eight investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $53.67.

NASDAQ:PCRX opened at $44.09 on Tuesday. The company has a 50-day moving average of $44.53 and a 200-day moving average of $42.09. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of -2,203.40, a PEG ratio of 2.22 and a beta of 1.31. Pacira Biosciences has a 52 week low of $27.46 and a 52 week high of $52.49. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.63 and a current ratio of 5.37.

Pacira Biosciences (NASDAQ:PCRX) last announced its earnings results on Thursday, May 7th. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.30 by $0.23. The business had revenue of $105.68 million during the quarter, compared to analysts’ expectations of $101.64 million. Pacira Biosciences had a negative net margin of 0.02% and a positive return on equity of 13.89%. The firm’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter last year, the company posted $0.22 EPS. Sell-side analysts forecast that Pacira Biosciences will post 0.95 EPS for the current year.

In related news, VP Lauren Bullaro Riker sold 2,000 shares of Pacira Biosciences stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $42.81, for a total transaction of $85,620.00. Following the transaction, the vice president now owns 12,464 shares of the company’s stock, valued at approximately $533,583.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Charles A. Reinhart III sold 1,489 shares of Pacira Biosciences stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $46.33, for a total transaction of $68,985.37. Following the transaction, the chief financial officer now directly owns 14,847 shares in the company, valued at approximately $687,861.51. The disclosure for this sale can be found here. Insiders sold a total of 43,083 shares of company stock worth $2,019,772 in the last ninety days. Insiders own 6.20% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. State Street Corp lifted its stake in Pacira Biosciences by 5.6% in the first quarter. State Street Corp now owns 1,403,659 shares of the company’s stock valued at $47,065,000 after buying an additional 74,009 shares in the last quarter. Royal Bank of Canada lifted its stake in Pacira Biosciences by 73.7% in the first quarter. Royal Bank of Canada now owns 21,932 shares of the company’s stock valued at $736,000 after buying an additional 9,307 shares in the last quarter. Rice Hall James & Associates LLC lifted its stake in Pacira Biosciences by 50.6% in the first quarter. Rice Hall James & Associates LLC now owns 627,714 shares of the company’s stock valued at $21,047,000 after buying an additional 210,863 shares in the last quarter. State of Tennessee Treasury Department lifted its stake in Pacira Biosciences by 8.1% in the first quarter. State of Tennessee Treasury Department now owns 32,427 shares of the company’s stock valued at $1,087,000 after buying an additional 2,417 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Pacira Biosciences by 80.2% in the first quarter. AQR Capital Management LLC now owns 53,211 shares of the company’s stock valued at $1,784,000 after buying an additional 23,685 shares in the last quarter.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Further Reading: Why is a lock-up period needed for an IPO?

The Fly

Analyst Recommendations for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.